Teva Study Highlights Gaps In Tardive Dyskinesia Diagnosis And Treatment In LTC Facilities

Teva Pharmaceuticals announced study results revealing a significant gap in the diagnosis and treatment of tardive dyskinesia (TD) among long-term care (LTC) residents receiving antipsychotic drugs (APDs). The study found that only 1.1% of APD recipients were diagnosed with TD, and less than half of those diagnosed received the American Psychiatric Association's standard of care treatment (VMAT2i), with many receiving non-FDA approved treatments or no treatment at all, highlighting a need for improved TD evaluation and diagnosis in LTC settings.

Analysis

Teva Pharmaceuticals (TEVA) has highlighted a significant unmet medical need through a study on tardive dyskinesia (TD) treatment patterns in long-term care (LTC) facilities. The research indicates that among residents on antipsychotic drugs, only 1.1% were confirmed to have TD, while 5.6% were diagnosed with extrapyramidal syndrome, a broader category of drug-induced movement disorders. Critically, less than half of TD-diagnosed patients in LTC settings received the American Psychiatric Association's recommended standard of care, a vesicular monoamine transporter 2 inhibitor (VMAT2i). Instead, a majority were given non-FDA approved treatments like benztropine, and a notable 25% received no treatment at all. This points to a substantial gap in accurate diagnosis and appropriate management of TD, suggesting that the condition is frequently misidentified, undertreated, or improperly treated. Teva's publication of these findings implicitly positions the company to address this gap, potentially expanding the market for effective TD treatments, which aligns with the mildly positive sentiment (0.3 score) observed for TEVA. The study underscores the necessity for improved TD evaluation and adherence to standard care protocols in LTC environments.

Key Decisions for Investors

• Investors should consider the identified unmet medical need in tardive dyskinesia as a potential market expansion opportunity for Teva, particularly concerning its VMAT2 inhibitor offerings.
• Monitor Teva's strategies and success in penetrating the long-term care market with its TD treatments, given the highlighted deficiencies in current care.
• Assess the competitive landscape for TD therapies, as increased awareness driven by such studies could benefit all VMAT2i providers, and evaluate Teva's market share and positioning within this segment.